BIA has responded to a HMRC consultation on R&D tax relief advance clearances, supporting government's aim to reduce error and fraud, increasing certainty for R&D tax relief claimants.
Our response to the Government’s consultation highlights the value of secure health data access for biotechs, the risks of uncontrolled broker use, and more.
BIA has responded to the call for evidence, highlighting the urgent need to close the scale-up funding gap and calling for pension fund reform to keep innovation and economic growth in the UK.
BIA has responded to the DBT's consultation on potential UK tariffs in response to US measures, urging to protect life sciences supply chains, innovation, and patient access.
Our response supported stronger HMRC powers to reduce fraud in the R&D tax relief system while protecting legitimate claims that drive innovation and economic growth.
BIA welcomes this call for evidence, as, while not currently a focus of the NWF, the life sciences could play an essential role in ensuring the fund achieves its objectives.
We've responded to the joint Intellectual Property Office (IPO), Department for Science, Innovation and Technology (DSIT) and Department for Culture, Media, and Sport (DCMS) consultation on Copyright and Artificial Intelligence (AI).
In our submission, we reiterate the economic growth potential of UK life sciences, and welcome its recognition within the Industrial Strategy as a priority sector. We call for government to turn its attention to the six key areas outlined within the Industrial Strategy, and list a number of priority investments within them.
The BIA has responded to the DBT consultation on Invest 2035, welcoming this open consultation, as well as the government's designation of the life sciences as one of the key growth-driving sectors.
NHS England has published a consultation document which sets out proposals for updating the NHS Commercial Framework for New Medicines. The BIA has responded to the consultation on updating the NHS commercial framework for new medicines.
The BIA has responded to the consultation on the Budget Impact Test (BIT) threshold. We welcome the proposal to increase the BIT threshold as this will help to ensure timely patient access to innovative medicines.
The BIA has responded to the HM Treasury, Department for Work and Pensions, and Ministry of Housing, Communities and Local Government's consultation on the Pension Investment Review.
Our submission urges caution and careful consideration of the impacts on life sciences as the government determines how to move forward with the taxation of capital gains.
We call for stability and the retention of already established commitments and programmes including R&D tax relief, pensions reform, and various other funding mechanisms such as the UKRI and Innovate UK budgets.
